AASLD is actively monitoring events related to the COVID-19 pandemic and will provide timely information and resources to support health care providers in hepatology, liver transplantation and gastroenterology as well as their patients and caregivers. This resource page will be updated regularly as more data become available to the AASLD Leadership.
On This Page:
- "COVID-19 AND THE LIVER" WEBINAR SERIES
- AASLD CREATES EXPERT PANEL CONSENSUS STATEMENT: "VACCINES TO PREVENT COVID-19 INFECTION IN PATIENTS WITH LIVER DISEASE"
- FOR THE CLINICIAN
- AASLD'S CLINICAL AND PUBLIC POLICY POSITIONS
- AASLD'S "CLINICAL BEST PRACTICE ADVICE FOR HEPATOLOGY AND LIVER TRANSPLANT PROVIDERS DURING THE COVID-19 PANDEMIC: AASLD EXPERT PANEL CONSENSUS STATEMENT"
- FOR TRAINEES / EARLY CAREER HEALTH CARE PROFESSIONALS
- FOR PATIENTS
- AASLD MULTIMEDIA RESOURCES
- WHAT YOU CAN DO
- JOURNAL REFERENCES FOR COVID-19
- OTHER COVID-19 RESOURCES
- CORPORATE SUPPORT
"COVID-19 and the Liver" Webinar Series
In response to the COVID-19 pandemic, AASLD has created a series of webinars dedicated to ongoing discoveries and discussions about how it affects the care of liver patients. These webinars, including those in which we collaborated with sister organizations, are located on the "COVID-19 and the Liver Webinar Series" page.
AASLD Creates Expert Panel Consensus Statement: "Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease"
The goal of this document is to provide concise safety and efficacy data regarding the commercially available COVID-19 vaccines and their use in CLD patients and liver transplant recipients. Our intent is to provide clinically useful information for hepatologists, liver transplant care providers, and their patients. This online document will be updated regularly as more data become available and additional vaccines are authorized for use.
- Download AASLD's Expert Panel Consensus Statement Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease. [Updated: August 30, 2021]
- Download AASLD's Expert Panel document Vaccine Document Supplemental Materials. [Updated: August 30, 2021]
- Download AASLD's Expert Panel document Counseling Liver Disease Patients about COVID-19 Vaccination. [Updated: March 16, 2021]
For the Clinician
- Mental Health and Burnout Resources
- Joint Society Messages
Download AASLD's curated list of resources for mental health, stress and burnout.
AASLD's Clinical and Public Policy Positions
- The Administration
- Congress
- Centers for Disease Control and Prevention
- Centers for Medicare & Medicaid Services
AASLD joins 200 Organizations in Letter to Administration regarding PPE and Ventilators
AASLD's "Clinical Best Practice ADVICE for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD EXPERT PANEL CONSENSUS STATEMENT"
This document provides data on what is known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a basic template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and health care providers. This document will continue to evolve and be reviewed by the authors and AASLD Governing Board, and be revised and updated as needed in response to the COVID-19 pandemic.
- Read AASLD's Clinical Best Practice Advice for Hepatology and Liver Providers During the COVID-19 Pandemic. (View the Spanish version and Portuguese version here.) [Updated: March 9, 2021]
For Trainees / Early Career Health Care Professionals
Download the Q&A document from the "Trainee and Early Career Experience in Hepatology during COVID-19" webinar.
For Patients
- COVID-19 Vaccine Recommendations for Patients with Liver Disease [Updated: September 13,2021]
- COVID-19 and Chronic Liver Disease
- COVID-19 in Children and Teenagers With Liver Disease or Liver Transplant
- COVID-19 and Viral Hepatitis
- COVID-19 and Nonalcoholic Fatty Liver Disease
- COVID-19 Myth Busters
- COVID-19 and Liver Transplantation
- COVID-19 and Hepatocellular Carcinoma
- COVID-19 and Liver Cirrhosis
- COVID-19 and Autoimmune Liver Disease
- COVID-19 and Alcohol-associated Liver Disease
AASLD Multimedia Resources
- Dilemmas in clinical management
- Journal club audio podcasts
"How I Approach It" Series
- COVID-19 in Patients with Autoimmune-Mediated Chronic Liver Disease
Maureen Whitsett, MD
November 19, 2020
What You Can Do
- Actions You Can Take
AASLD seeks COVID-19 Manuscript Submissions
Read the letter from AASLD journal Editors-in-Chief David Cohen, Paul Martin and Gyongyi Szabo.
COVID-19 Discussion Community in Engage
AASLD members have an outlet to share and discuss COVID-19 and how it's affecting care delivery to patients with liver disease.
Write your Congressional Representatives and Senators
Join us and make your voice heard: Use our online advocacy tool to send an email to your legislators about how COVID-19 is impacting you and what needs to be done to protect you, your colleagues and your patients during this urgent time.
Journal References for COVID-19
- AASLD Journal Articles
- Resources from Other Publishers
HEPATOLOGY
- HEPATOLOGY – Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
- HEPATOLOGY – With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States
- HEPATOLOGY – Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States
- HEPATOLOGY – Current and past infections of hepatitis B virus do not increase mortality in patients with COVID‐19
- HEPATOLOGY – Outcome of COVID‐19 in Patients with Autoimmune Hepatitis: an International Multi‐Centre Study
- HEPATOLOGY – AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID‐19 Infection in Patients with Liver Disease
- HEPATOLOGY – COVID‐19 and Liver Cirrhosis: focus on the non‐classical renin‐angiotensin system and implications for therapy
- HEPATOLOGY – Cirrhosis and SARS‐CoV‐2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
- HEPATOLOGY – Addressing Social Determinants of Liver Disease during the COVID‐19 Pandemic and Beyond: A Call to Action
- HEPATOLOGY – Liver Injury in Liver Transplant Recipients with Coronavirus Disease 2019 (COVID‐19): US Multicenter Experience
- HEPATOLOGY – Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS‐CoV‐2 Pandemic
- HEPATOLOGY – Clinical Research in Hepatology in the COVID‐19 Pandemic and Post‐Pandemic Era: Challenges and the Need for Innovation
- HEPATOLOGY – Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network
- HEPATOLOGY – Abnormal liver function tests in COVID‐19 patients: relevance and potential pathogenesis
- HEPATOLOGY – Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID‐19: Systematic Review and Meta‐analysis
- HEPATOLOGY – Clinical Features of COVID‐19‐Infected Patients With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
- HEPATOLOGY – Acute Liver Injury in COVID‐19: Prevalence and Association with Clinical Outcomes in a Large US Cohort
- HEPATOLOGY – Liver Biochemistries in Hospitalized Patients With COVID‐19
- HEPATOLOGY – COVID‐19 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol‐Associated Liver Disease
- HEPATOLOGY – Longitudinal association between markers of liver injury and mortality in COVID‐19 in China
- HEPATOLOGY – Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
- HEPATOLOGY – Telemedicine in Liver Disease and Beyond: Can the COVID‐19 Crisis Lead to Action?
- HEPATOLOGY – Perioperative Presentation of COVID‐19 Disease in a Liver Transplant Recipient
Clinical Liver Disease
- May 2020 issue – COVID-19 and Liver Disease
Liver Transplantation
- Liver Transplantation – Impact of the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak on Pediatric Liver Transplant Recipients in Lombardy, Northern Italy
- Liver Transplantation – Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
- Liver Transplantation – Coronavirus Disease 2019 Infection Requires Strengthening of the Chronic Care Model: The Impact on Liver Transplant Practice at a High‐Volume Center in Italy
- Liver Transplantation – Outcomes of Coronavirus Disease 2019 in Living Donor Liver Transplant Recipients
- Liver Transplantation – Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center‐Level Variability
- Liver Transplantation – In‐Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of Coronavirus Disease 2019, and Areas of Opportunity
- Liver Transplantation – Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?
- Liver Transplantation – A Multicentric Experience on Living Donor Liver Transplantation in COVID‐19 Hotspots in India
- Liver Transplantation – Liver transplantation in a patient with human immunodeficiency virus and COVID‐19
- Liver Transplantation – Changes in liver transplant center practice in response to COVID-19: Unmasking dramatic center-level variability
- Liver Transplantation – Liver Transplantation in an ICU dominated by COVID‐19
- Liver Transplantation – Preliminary Analysis of the Impact of COVID‐19 Outbreak on Italian Liver Transplant Programs
- Liver Transplantation – Changes in liver transplant center practice in response to COVID‐19: Unmasking dramatic center‐level variability
- Liver Transplantation – Coronaviruses and immunosuppressed patients. The facts during the third epidemic
Hepatology Communications
- Hepatology Communications – COVID-19 and liver injury: role of inflammatory endotheliopathy, platelet dysfunction and thrombosis
- Hepatology Communications – Correlation between Clinical and Pathological Findings of Liver Injury in 27 Patients with Lethal COVID-19 Infections in Brazil
- Hepatology Communications – Independent Predictors of Mortality Among Patients with Non-alcoholic Fatty Liver Disease (NAFLD) Hospitalized with COVID-19 Infection
- Hepatology Communications – COVID-19 and the uncovering of healthcare disparities in the US, UK and Canada: Call to action
- Hepatology Communications – COVID‐19‐related downscaling of in‐hospital liver care decreased patient satisfaction and increased liver‐related mortality
- Hepatology Communications – Letter to the Editor: Autoimmune Hepatitis and COVID‐19: disease outcomes and tacrolimus use
- Hepatology Communications – Impact of COVID‐19 in liver disease progression
- Hepatology Communications – Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID‐19 patients as prognostic markers
- Hepatology Communications – FIB‐4 Predicts Need for Mechanical Ventilation in a Multi‐ethnic National cohort of COVID‐19
- Hepatology Communications – The COVID‐19 medicine remdesivir is therapeutically activated by carboxylesterase‐1 AND excessive hydrolysis increases cytotoxicity
- Hepatology Communications – Feasibility, outcomes, and safety of tele‐hepatology services during the COVID‐19 pandemic
- Hepatology Communications – COVID‐19 Aftershocks on Alcohol‐associated Liver Disease: An Early Cross‐Sectional Report from the U.S. Epicenter
- Hepatology Communications – Liver fibrosis index FIB‐4 is associated with mortality in COVID‐19
- Hepatology Communications – Hepatic Predictors of Mortality in SARS‐CoV2: Role of Initial AST/ALT and Pre‐Existing Cirrhosis
- Hepatology Communications – Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study
- Hepatology Communications – Liver Injury in Hospitalized Patients with COVID‐19 Correlates with Hyper Inflammatory Response and Elevated IL‐6
- Hepatology Communications – The Impact of COVID‐19 on Organ Donation, Procurement and Liver Transplantation in the United States
- Hepatology Communications – Antibody response to SARS‐Co‐V‐2, diagnostic and therapeutic implications
- Hepatology Communications – Clinical features of COVID‐19 patients with non‐alcoholic fatty liver disease
- Hepatology Communications – How to survive Covid‐19 even if the vaccine fails
- Hepatology Communications – Liver injury as a surrogate for inflammation and predictor of outcomes in COVID‐19
- Hepatology Communications – Liver Chemistries in Patients with COVID‐19 Who Discharged alive or Died: A Meta‐analysis
- Hepatology Communications – Liver Care and Surveillance: The Global Impact of COVID-19 Pandemic
- Hepatology Communications – Urgent liver transplantation soon after recovery from COVID‐19 in a patient with decompensated liver cirrhosis
- Hepatology Communications – γ‐Glutamyltransferase Elevations Are Frequent in Patients With COVID‐19: A Clinical Epidemiologic Study
- Hepatology Communications – Liver Transplantation in the Time of COVID19: Barriers and Ethical considerations for Management and Next Steps
- Hepatology Communications – Coronavirus Disease 2019 (COVID‐19) in autoimmune hepatitis: a lesson from immunosuppressed patients
Other COVID-19 Resources
- American Medical Association
- Centers for Disease Control and Prevention
- Centers for Medicare and Medicaid Services
- Fellow Hepatology, GI and Transplant Organizations
- Food & Drug Administration
- Health & Human Services
- Health Care Resiliency Taskforce
- National Institutes of Health
- SECURE-Cirrhosis
- AABB
- AASLD News
- For Patients
Corporate Support
AASLD is grateful to AbbVie for its generous support of the AASLD COVID-19 Resource Center.
Learn more about the Corporate Support for AASLD's COVID-19 resource center.